Clinical trials: PD-L1
Stage III Breast Cancer, Stage IIIA Breast Cancer
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
This phase I/II trial studies the side effects and best dose of idasanutlin when given together with atezolizumab, and to see how well atezolizumab and cobimetinib or idasanutlin work in treating participants with stage IV…
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT03566485
- Testing
- Atezolizumab, Cobimetinib, Idasanutlin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and…
- Conditions
- Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
- Trial name
- NCT07144280
- Testing
- PF-08046054, Docetaxel monotherapy
- Where
- 447 sites in United States, Argentina and 27 more
- Volunteers
- 680 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1…
- Trial name
- NCT05431270
- Testing
- Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Phanes Therapeutics
Small-cell Lung Cancer
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by…
- Trial name
- NCT05552846
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
Pancreatic Adenocarcinoma
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma
Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an…
- Trial name
- NCT05228808
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Advanced Solid Tumors
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1 (PD-1).
- Trial name
- NCT03379259
- Testing
- BGB-A333, BGB-A317
- Where
- 8 sites in Australia, New Zealand and 1 more
- Volunteers
- 39 people
- Sponsor
- BeiGene
Uterine Cervical Neoplasms
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.
- Trial name
- NCT04246489
- Testing
- Bintrafusp alfa
- Where
- 73 sites in United States, Argentina and 10 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Head-and-neck Squamous-cell Carcinoma
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
The primary hypothesis is that the objective response rate (ORR) with nab-paclitaxel and nivolumab will be significantly higher than the historical control (ORR 30%).
- Trial name
- NCT04831320
- Testing
- nab-paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
Asymptomatic Myeloma
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM).
- Trial name
- NCT02784483
- Testing
- Atezolizumab (1200mg via IV infusion)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Yale University
Non-Small Cell Lung Cancer, NSCLC
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS<50% NSCLC patients who receive reduced dose chemotherapy in combination with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06731413
- Testing
- Reduced Dose of Chemotherapy and Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Non-small Cell Lung Cancer (NSCLC)
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung…
- Trial name
- NCT07215962
- Testing
- Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-based chemotherapy, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
This is a clinical trial that aims to evaluate whether adding a bile acid called tauroursodeoxycholic acid (TUDCA) can improve the effects of immunotherapy in patients with advanced liver cancer (hepatocellular carcinoma).
- Trial name
- NCT07064668
- Testing
- TUDCA (Tauroursodeoxycholic Acid) Supplementation, Immune checkpoint inhibitor (ICI)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable…
- Trial name
- NCT04220866
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Non Small Cell Lung Cancer
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients'…
- Conditions
- Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III, NSCLC
- Trial name
- DART (NCT04392505)
- Testing
- Durvalumab Injection
- Where
- 10 sites in Estonia, Finland and 2 more
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
Carcinoma, Squamous Cell, Non-small-cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976362
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
Purposes of this study are : Characterization of polyfunctionality of anti-tumor T lymphocytes using in vitro inhibition of PD-1/PDL-1 pathway Study and comparison of polyfunctionality of anti-tumor T lymphocytes in cohorts of…
- Trial name
- POLYTCANCER (NCT02880046)
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Uterine Cervical Neoplasms
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation.
- Trial name
- NCT05492123
- Testing
- Nivolumab 40 mg in 4 ml Injection, Ipilimumab 200 MG in 40 ML Injection, Chemoradiation
- Where
- 14 sites in Brazil
- Volunteers
- 112 people
- Sponsor
- Hospital Israelita Albert Einstein
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.